Women experiencing debilitating menopausal symptoms should be offered hormone replacement therapy (HRT) as the first-line treatment, the National Institute for Health and Care Excellence (NICE) has reaffirmed. The renewed emphasis on existing clinical guidelines aims to ensure consistent care across the NHS and address concerns that some women have struggled to access appropriate treatment.
NICE's guidance has consistently recognised HRT as highly effective for managing symptoms such as hot flushes, night sweats, mood changes, and vaginal dryness – symptoms that can severely disrupt daily life for many women. This latest clarification is designed to give healthcare professionals confidence in recommending HRT where appropriate, following thorough discussions with patients about their individual circumstances.
The guidelines outline different HRT formulations tailored to women's needs: oestrogen-only preparations for women who have had a hysterectomy, and combined oestrogen and progestogen therapy for those with an intact uterus. Crucially, the approach emphasises individualised care, with treatment type, dosage, and duration carefully matched to each woman's symptoms, medical history, and personal preferences, with regular monitoring to ensure both effectiveness and safety.
This renewed focus addresses longstanding concerns about inconsistent access to HRT and varying levels of understanding among both patients and some healthcare professionals. By clearly positioning HRT as first-line treatment, NICE hopes to reduce the time women spend enduring symptoms that could be effectively managed, whilst empowering them to seek appropriate help.
For women across the UK, improved adherence to these guidelines should mean better outcomes and more consistent care. The guidance encourages open conversations between women and their doctors about HRT's benefits and risks, helping to counter misinformation and ensure informed decision-making. This aligns with the Government's broader commitment to improving women's health outcomes during menopause.
Importantly, whilst HRT is recommended as first-line treatment, NICE acknowledges that not all women can or wish to use it. The guidelines ensure alternative treatments and lifestyle approaches remain part of comprehensive care plans, maintaining the patient-centred approach that underpins all NHS menopause care.